RhumbLine Advisers’s PhenomeX Inc. Common Stock CELL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-2,123
| Closed | -$2.12K | – | 4321 |
|
|
2023
Q3 | $2.12K | Sell |
2,123
-4,524
| -68% | -$3.47K | ﹤0.01% | 4106 |
|
|
2023
Q2 | $3.26K | Sell |
6,647
-81,699
| -92% | -$66.8K | ﹤0.01% | 4150 |
|
|
2023
Q1 | $102K | Buy |
88,346
+1,714
| +2% | +$3.13K | ﹤0.01% | 2852 |
|
|
2022
Q4 | $232K | Sell |
86,632
-53
| -0.1% | -$140 | ﹤0.01% | 2758 |
|
|
2022
Q3 | $248K | Buy |
86,685
+4,468
| +5% | +$19K | ﹤0.01% | 2819 |
|
|
2022
Q2 | $409K | Buy |
82,217
+31,238
| +61% | +$164K | ﹤0.01% | 2599 |
|
|
2022
Q1 | $362K | Buy |
50,979
+1,951
| +4% | +$16.1K | ﹤0.01% | 2569 |
|
|
2021
Q4 | $891K | Sell |
49,028
-802
| -2% | -$17.3K | ﹤0.01% | 2255 |
|
|
2021
Q3 | $975K | Buy |
49,830
+4,583
| +10% | +$174K | ﹤0.01% | 2230 |
|
|
2021
Q2 | $2.03M | Buy |
45,247
+24,185
| +115% | +$1.12M | ﹤0.01% | 1941 |
|
|
2021
Q1 | $1.06M | Buy |
21,062
+11,819
| +128% | +$806K | ﹤0.01% | 2168 |
|
|
2020
Q4 | $826K | Buy |
9,243
+2,359
| +34% | +$198K | ﹤0.01% | 2226 |
|
|
2020
Q3 | $526K | Buy |
+6,884
| New | +$437K | ﹤0.01% | 2270 |
|
RhumbLine Advisers's CELL Position: Q4 2023 in Review
RhumbLine Advisers sold out of PhenomeX Inc. Common Stock (CELL) in Q4 2023, closing a stake of 2,123 shares — an estimated $2.12K sold.
RhumbLine Advisers first reported a position in CELL in Q3 2020 and held it in 13 quarters. The position peaked at $2.03M in Q2 2021. 0 funds tracked by Wall St. Rank hold CELL as of Q4 2023.
- RhumbLine Advisers reported no remaining PhenomeX Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
- RhumbLine Advisers sold 2,123 PhenomeX Inc. Common Stock shares in Q4 2023, an estimated $2.12K.
- RhumbLine Advisers first reported a position in PhenomeX Inc. Common Stock in Q3 2020 and held it in 13 quarters.
- RhumbLine Advisers's PhenomeX Inc. Common Stock position peaked at $2.03M in Q2 2021.
- 0 funds tracked by Wall St. Rank held PhenomeX Inc. Common Stock as of Q4 2023.
Based on RhumbLine Advisers's 13F filing for Q4 2023, filed 8 Feb 2024.